Cronos Group Inc. (CRON)
USD 1.84
(-1.6%)
USD 1.84
(-1.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 43.73 Million USD | -39.29% |
| 2022 | 72.04 Million USD | 13.52% |
| 2021 | 63.46 Million USD | -70.82% |
| 2020 | 217.51 Million USD | -36.29% |
| 2019 | 341.41 Million CAD | 839.82% |
| 2018 | 36.32 Million CAD | 211.59% |
| 2017 | 11.65 Million CAD | 69.91% |
| 2016 | 6.86 Million CAD | 215.09% |
| 2015 | 2.17 Million CAD | 258.74% |
| 2014 | 607.04 Thousand CAD | 58.86% |
| 2013 | 382.12 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 35.25 Million USD | -1.31% |
| 2024 Q1 | 35.72 Million USD | -18.33% |
| 2023 Q4 | 43.73 Million USD | 31.15% |
| 2023 FY | 43.73 Million USD | -39.29% |
| 2023 Q1 | 33.17 Million USD | -53.95% |
| 2023 Q2 | 31.67 Million USD | -4.52% |
| 2023 Q3 | 33.34 Million USD | 5.28% |
| 2022 Q2 | 47.25 Million USD | -4.8% |
| 2022 Q3 | 46.22 Million USD | -2.17% |
| 2022 Q1 | 49.63 Million USD | -21.8% |
| 2022 FY | 72.04 Million USD | 13.52% |
| 2022 Q4 | 72.04 Million USD | 55.85% |
| 2021 Q1 | 313 Million USD | 43.9% |
| 2021 Q4 | 63.46 Million USD | -19.44% |
| 2021 Q3 | 78.77 Million USD | -62.25% |
| 2021 FY | 63.46 Million USD | -70.82% |
| 2021 Q2 | 208.69 Million USD | -33.32% |
| 2020 Q1 | 212.65 Million USD | -37.71% |
| 2020 Q2 | 247.24 Million USD | 16.26% |
| 2020 Q4 | 217.51 Million USD | 40.84% |
| 2020 FY | 217.51 Million USD | -36.29% |
| 2020 Q3 | 154.44 Million USD | -37.53% |
| 2019 Q2 | 1.09 Billion CAD | -15.07% |
| 2019 Q4 | 341.41 Million CAD | -26.46% |
| 2019 Q3 | 464.26 Million CAD | -57.76% |
| 2019 FY | 341.41 Million CAD | 839.82% |
| 2019 Q1 | 1.29 Billion CAD | 3462.75% |
| 2018 Q1 | 6.92 Million CAD | -40.56% |
| 2018 Q3 | 9.43 Million CAD | 51.89% |
| 2018 Q4 | 36.32 Million CAD | 285.19% |
| 2018 FY | 36.32 Million CAD | 211.59% |
| 2018 Q2 | 6.2 Million CAD | -10.4% |
| 2017 Q3 | 9.58 Million CAD | 203.37% |
| 2017 Q4 | 11.65 Million CAD | 21.59% |
| 2017 FY | 11.65 Million CAD | 69.91% |
| 2017 Q2 | 3.16 Million CAD | -47.3% |
| 2017 Q1 | 5.99 Million CAD | -12.6% |
| 2016 Q2 | 318.69 Thousand CAD | -84.46% |
| 2016 FY | 6.86 Million CAD | 215.09% |
| 2016 Q1 | 2.05 Million CAD | -5.84% |
| 2016 Q4 | 6.86 Million CAD | -0.22% |
| 2016 Q3 | 6.87 Million CAD | 2057.84% |
| 2015 Q2 | 1.59 Million CAD | 123.41% |
| 2015 FY | 2.17 Million CAD | 258.74% |
| 2015 Q3 | 1.68 Million CAD | 5.86% |
| 2015 Q4 | 2.17 Million CAD | 28.87% |
| 2015 Q1 | 714.5 Thousand CAD | 0.0% |
| 2014 Q2 | 36.45 Thousand CAD | 0.0% |
| 2014 Q3 | 39.3 Thousand CAD | 7.81% |
| 2014 FY | 607.04 Thousand CAD | 58.86% |
| 2013 FY | 382.12 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 90.727% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 73.316% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 95.386% |
| Cosmos Health Inc. | 30.25 Million USD | -44.57% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -415.116% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 93.381% |
| Incannex Healthcare Limited | 5.83 Million USD | -650.19% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 9.72% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 80.102% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -19824.233% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -612.36% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -612.36% |
| SCYNEXIS, Inc. | 55.45 Million USD | 21.125% |
| Safety Shot Inc | 3.89 Million USD | -1023.73% |
| Theratechnologies Inc. | 98.63 Million USD | 55.66% |
| Alpha Teknova, Inc. | 38.55 Million USD | -13.45% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -217.98% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 93.79% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -399.498% |
| Dynavax Technologies Corporation | 375.02 Million USD | 88.338% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 94.649% |
| Radius Health, Inc. | 804.29 Million USD | 94.562% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -375.567% |
| Alvotech | 1.88 Billion USD | 97.677% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 68.046% |
| SIGA Technologies, Inc. | 57.97 Million USD | 24.563% |
| Shineco, Inc. | 47.6 Million USD | 8.121% |
| Silver Spike Investment Corp. | 3 Million USD | -1353.108% |
| Journey Medical Corporation | 56.49 Million USD | 22.59% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -105.182% |
| Embecta Corp. | 2.03 Billion USD | 97.852% |
| Harrow Health, Inc. | 241.75 Million USD | 81.909% |
| Procaps Group, S.A. | 462.06 Million USD | 90.535% |
| Biofrontera Inc. | 23.13 Million USD | -89.015% |
| DURECT Corporation | 30.4 Million USD | -43.84% |
| PainReform Ltd. | 2.69 Million USD | -1525.272% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 91.028% |
| OptiNose, Inc. | 194.33 Million USD | 77.494% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -108.484% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 75.885% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 16.719% |
| ProPhase Labs, Inc. | 42.54 Million USD | -2.802% |
| Phibro Animal Health Corporation | 725.54 Million USD | 93.972% |
| Procaps Group S.A. | 462.06 Million USD | 90.535% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -211.91% |
| Viatris Inc. | 27.21 Billion USD | 99.839% |
| Rockwell Medical, Inc. | 30.88 Million USD | -41.623% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 51.608% |
| Tilray Brands, Inc. | 892.11 Million USD | 95.097% |
| PetIQ, Inc. | 645.22 Million USD | 93.222% |
| Talphera, Inc. | 6.29 Million USD | -595.327% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 95.71% |
| Alimera Sciences, Inc. | 107.35 Million USD | 59.26% |
| Assertio Holdings, Inc. | 148.41 Million USD | 70.531% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -2206.798% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 74.775% |
| Hempacco Co., Inc. | 18.82 Million USD | -132.362% |
| Alvotech | 1.88 Billion USD | 97.677% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 94.764% |
| Kamada Ltd. | 109.96 Million USD | 60.228% |
| Currenc Group, Inc. | 177.67 Million USD | 75.384% |
| Indivior PLC | 1.95 Billion USD | 97.759% |
| Evoke Pharma, Inc. | 9.64 Million USD | -353.314% |
| Flora Growth Corp. | 17.22 Million USD | -153.955% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -415.116% |
| Evolus, Inc. | 209.68 Million USD | 79.142% |
| HUTCHMED (China) Limited | 536.38 Million USD | 91.846% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 94.993% |
| Akanda Corp. | 12.66 Million USD | -245.224% |